Lyxumia (lixisenatide; Sanofi) is a member of the glucagon-like peptide-1 (GLP-1) agonist class. GLP-1 agonists are incretin mimetics, mimicking the endogenous gut hormone GLP-1, which stimulates insulin-secreting beta cells in the pancreas. This triggers glucose-dependent insulin secretion, suppressing glucagon secretion, and thereby decreases plasma glucose levels. The major advantage of this class is the associated weight loss, as obesity is a common co-morbidity among type 2 diabetes patients. GLP-1 agonists also delay gastric emptying, thus increasing satiety and suppressing appetite.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Lyxumia : Diabetes type 2
LIST OF FIGURES
9 Figure 1: Lyxumia for type 2 diabetes – SWOT analysis
10 Figure 2: Datamonitor Healthcare drug assessment of Lyxumia
11 Figure 3: Datamonitor Healthcare drug assessment scorecard for Lyxumia compared to Victoza
13 Figure 4: Lyxumia sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES 4 Table 1: Lyxumia drug profile
6 Table 2: Overview of pivotal trial data for Lyxumia
14 Table 3: Lyxumia sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.